MRCP UK EXAMINATIONS

Detailed explanation-1: -Apixaban is a novel oral anticoagulant (NOAC) approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with non-valvular atrial fibrillation to reduce the risk of stroke and blood clots. Later, in 2014, it was approved to treat deep venous thrombosis (DVT) and pulmonary embolism (PE).

Detailed explanation-2: -Eliquis is a novel oral anticoagulant that specifically inhibits Factor Xa.

Detailed explanation-3: -In recent years, four direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban and edoxaban, have been compared with warfarin for stroke prevention in AF, in large, phase 3, randomised, controlled trials (RCTs).

Detailed explanation-4: -Oral Anticoagulant | Rx ELIQUIS® (apixaban) Safety Info. DVT/PE=deep vein thrombosis/pulmonary embolism. NVAF=nonvalvular atrial fibrillation.